In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BMS partners Sprycel and Ixempra with Otsuka

Executive Summary

In a ten-year agreement that takes effect in 2010, Bristol-Myers Squibb has partnered its leukemia treatment Sprycel (dasatinib) and advanced breast cancer drug Ixempra (ixabepilone) with Otsuka Pharmaceutical in the US, Europe, and Japan. The deal includes present and future indications of the products.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Royalty or Profit Split Information
    • Marketing (Licensing)

Related Companies